Early-stage life sciences companies are increasingly in the spotlight these days, with an uptick in investor interest and M&A activity in the space. In “The Relationship between Funding and Exit Paths”, MABA founder Yaniv Sneor shares some background about our group and discusses potential exit strategies a young life science company may consider and how an exit strategy will, in most cases, determine the funding
